Effect of Nicotine Pouches on The Underlying Normal Electrocardiogram

NCT07057440 — Not applicable, Completed, 20 participants, Ekim Seven

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Effect of Nicotine Pouches on The Underlying Normal Electrocardiogram A Double-Blinded, Placebo-Controlled Cross-over Study Exploring the Dose-Response Effects of Nicotine Pouches on Heart Rate and the Electrocardiogram ACRONYM: The NICOTUNE Study

RegistryNCT07057440, acronym NICOTUNE
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, crossover, masking: quadruple, prevention
Enrollment20 (Actual)
SponsorEkim Seven (Other)
ConditionsHeart Rate, ECG, Vital Sign Monitoring, Symptoms
InterventionsHigh-dose Nicotine Pouch, Low Dose Nicotine Pouch, Placebo Pouch (Other)
Datesstart 2025-06-27, primary completion 2025-10-31, completion 2025-10-31, first posted 2025-07-09, last updated 2025-12-11
Locations1 site in Denmark

Related Papers Related Patents Related Grants Related Experts
All trials for Heart Rate All trials for ECG All trials of High-dose Nicotine Pouch All trials of Low Dose Nicotine Pouch

-Summary

Nicotine pouches (NPs) are increasingly being used by children, adolescents, and adults, and are often presented as a less harmful alternative to, for example, smoking. The ability to use these products discreetly (unlike smoking) makes them an attractive option for individuals who wish to avoid the stigma that smokers may sometimes experience.

Nicotine is a well-known addictive substance that affects many organ systems, including the heart and circulatory system. The amount of nicotine in NPs varies greatly, but the pouches can contain large amounts of nicotine compared to the content of a single cigarette. While many studies have previously examined the effects of smoking and other nicotine products on the heart and circulatory system, specific data on the effects of NPs on these same systems are rather limited.

In light of the above, the investigators have planned a study to investigate whether NPs affect the circulatory system and heart rate, assessed through electrocardiography (ECG) and vital signs (i.e., pulse, blood pressure, respiratory rate, and more).

The investigators hypothesis is that the nicotine content in NPs leads to notable changes in the aforementioned measurements and could therefore potentially be associated with an increased health risk.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Placebo pouch armPlacebo comparatorOther: Placebo Pouch
Low-dosage nicotine pouch armExperimentalOther: Low Dose Nicotine Pouch
High-dosage nicotine pouch armExperimentalOther: High-dose Nicotine Pouch
  • High-dose Nicotine Pouch (Other): A High Dose Nicotine Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions. After 20 minutes pouches are removed from the oral cavity and disposed.
  • Low Dose Nicotine Pouch (Other): A Low Dose Nicotine Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions. After 20 minutes pouches are removed from the oral cavity and disposed.
  • Placebo Pouch (Other): A Placebo Pouch are placed and held in the oral cavity (between the gum and lip) for 20 minutes, as per standard use instructions. After 20 minutes pouches are removed from the oral cavity and disposed.

+Outcome measures

Primary outcomes

  • Heart rate [10 and 20 minutes (just before disposal) after the placement of the nicotine pouch in the oral cavity]: Changes in HR (beats/minute) obtained from an ECG recorded 20 minutes after nicotine pouch administration compared to the baseline ECG.

Secondary outcomes

  • ECG parameters [10 and 20 minutes (just before disposal) after the placement of the nicotine pouch in the oral cavity]: Changes in various ECG parameters from baseline: • PR interval (msec) • QRS duration (msec) • QT interval (corrected, QTc) (msec) • HRV (msec)
  • ST-T segment changes [10 and 20 minutes (just before disposal) after the placement of the nicotine pouch in the oral cavity]: ST-T segment changes, e.g., depression/elevation/inversion (mm) from baseline
  • Arrhythmias [10 and 20 minutes (just before disposal) after the placement of the nicotine pouch in the oral cavity]: Any arrhythmias e.g., ectopic beats (yes/no, numerical) detected on the ECG compared with baseline ECG

Other outcomes

  • Blood pressure [10 and 20 minutes (just before disposal) after the placement of the nicotine pouch in the oral cavity]: Changes in Blood pressure (mmHg)
  • Respiratory rate [10 and 20 minutes (just before disposal) after the placement of the nicotine pouch in the oral cavity]: Changes in Respiratory rate (breaths per minute)
  • Oxygen saturation [10 and 20 minutes (just before disposal) after the placement of the nicotine pouch in the oral cavity]: Changes in Oxygen saturation (percentage/%)
  • Body temperature [10 and 20 minutes (just before disposal) after the placement of the nicotine pouch in the oral cavity]: Changes in Body temperature (degree Celsius)
  • Self-reported symptoms [10 and 20 minutes (just before disposal) after the placement of the nicotine pouch in the oral cavity]: Subjective symptoms self-reported by the participants during the intervention using VAS-questionnaire of 10 known nicotine effect/symptoms (nausea, dizziness, lightheadedness, nervousness, sweatiness, headache, excessive salivation, heart pounding, confusion, and weakness).

+Eligibility

Sex: All, ages: 18 Years to 70 Years, accepts healthy volunteers

Inclusion Criteria:

* Adults aged 18-70 years.
* Regular (defined as daily) or occasional (generally defined as nondaily) nicotine users (e.g., cigarettes, vaping, or nicotine pouches).
* Willingness to abstain from nicotine, caffeine (including caffeine containing energy drinks), and alcohol for 6 hours prior to the session

Exclusion Criteria:

* History of cardiovascular conditions.
* Medications affecting cardiac conduction or autonomic function (e.g., antiarrhythmic drugs).
* Pregnancy or breastfeeding.
* Current illness or infection.
* History of substance abuse.

+Locations (1)

FacilityCityCountryStatus
Department of cardiology, Copenhagen University Hospital, Amager & HvidovreHvidovreDenmark